# Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

> **NCT04099251** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 790 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Nivolumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04099251
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-28
- **Primary completion:** 2022-06-28
- **Final completion:** 2027-06-29
- **Target enrollment:** 790 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04099251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04099251, "Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04099251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*